294 related articles for article (PubMed ID: 26991136)
1. β-asarone and levodopa co-administration increase striatal dopamine level in 6-hydroxydopamine induced rats by modulating P-glycoprotein and tight junction proteins at the blood-brain barrier and promoting levodopa into the brain.
Huang L; Deng M; He Y; Lu S; Ma R; Fang Y
Clin Exp Pharmacol Physiol; 2016 Jun; 43(6):634-43. PubMed ID: 26991136
[TBL] [Abstract][Full Text] [Related]
2. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
[TBL] [Abstract][Full Text] [Related]
3. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
Huang L; Deng M; Zhang S; Fang Y; Li L
Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
[TBL] [Abstract][Full Text] [Related]
4. β-asarone and levodopa co-administration protects against 6-hydroxydopamine-induced damage in parkinsonian rat mesencephalon by regulating autophagy: down-expression Beclin-1 and light chain 3B and up-expression P62.
Huang LP; Deng MZ; He YP; Fang YQ
Clin Exp Pharmacol Physiol; 2015 Mar; 42(3):269-77. PubMed ID: 25424835
[TBL] [Abstract][Full Text] [Related]
5. Dynamic changes of five neurotransmitters and their related enzymes in various rat tissues following β-asarone and levodopa co-administration.
Huang L; Deng M; Fang Y; Li L
Exp Ther Med; 2015 Oct; 10(4):1566-1572. PubMed ID: 26622527
[TBL] [Abstract][Full Text] [Related]
6. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
Dominguez-Meijide A; Villar-Cheda B; Garrido-Gil P; Sierrra-Paredes G; Guerra MJ; Labandeira-Garcia JL
Neuropharmacology; 2014 Jan; 76 Pt A():156-68. PubMed ID: 23973568
[TBL] [Abstract][Full Text] [Related]
7. Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment.
Cenci MA; Tranberg A; Andersson M; Hilbertson A
Neuroscience; 1999; 94(2):515-27. PubMed ID: 10579213
[TBL] [Abstract][Full Text] [Related]
8. Interactions of the tricyclic antidepressant drug amitriptyline with L-DOPA in the striatum and substantia nigra of unilaterally 6-OHDA-lesioned rats. Relevance to motor dysfunction in Parkinson's disease.
Kamińska K; Lenda T; Konieczny J; Wardas J; Lorenc-Koci E
Neurochem Int; 2018 Dec; 121():125-139. PubMed ID: 30290201
[TBL] [Abstract][Full Text] [Related]
9. Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Shin KS; Choi HS; Zhao TT; Suh KH; Kwon IH; Choi SO; Lee MK
Arch Pharm Res; 2013 Jun; 36(6):759-67. PubMed ID: 23539311
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective Effects of β-Asarone Against 6-Hydroxy Dopamine-Induced Parkinsonism via JNK/Bcl-2/Beclin-1 Pathway.
Zhang S; Gui XH; Huang LP; Deng MZ; Fang RM; Ke XH; He YP; Li L; Fang YQ
Mol Neurobiol; 2016 Jan; 53(1):83-94. PubMed ID: 25404088
[TBL] [Abstract][Full Text] [Related]
11. Effects of safinamide on the glutamatergic striatal network in experimental Parkinson's disease.
Sciaccaluga M; Mazzocchetti P; Bastioli G; Ghiglieri V; Cardinale A; Mosci P; Caccia C; Keywood C; Melloni E; Padoani G; Vailati S; Picconi B; Calabresi P; Tozzi A
Neuropharmacology; 2020 Jun; 170():108024. PubMed ID: 32142791
[TBL] [Abstract][Full Text] [Related]
12. Effect of repeated electroconvulsive shock on striatal L-dopa and dopamine metabolism: an in vivo study.
Brannan T; Martínez-Tica J; Yahr MD
J Neural Transm Park Dis Dement Sect; 1993; 6(1):35-44. PubMed ID: 7692872
[TBL] [Abstract][Full Text] [Related]
13. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
Carta M; Lindgren HS; Lundblad M; Stancampiano R; Fadda F; Cenci MA
J Neurochem; 2006 Mar; 96(6):1718-27. PubMed ID: 16539687
[TBL] [Abstract][Full Text] [Related]
14. Effects of L-Dopa on circadian rhythms of 6-OHDA striatal lesioned rats: a radiotelemetric study.
Boulamery A; Simon N; Vidal J; Bruguerolle B
Chronobiol Int; 2010 Jan; 27(2):251-64. PubMed ID: 20370468
[TBL] [Abstract][Full Text] [Related]
15. Histamine H(3) receptor ligands modulate L-dopa-evoked behavioral responses and L-dopa derived extracellular dopamine in dopamine-denervated rat striatum.
Nowak P; Bortel A; Dabrowska J; Biedka I; Slomian G; Roczniak W; Kostrzewa RM; Brus R
Neurotox Res; 2008; 13(3-4):231-40. PubMed ID: 18522902
[TBL] [Abstract][Full Text] [Related]
16. β-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1.
Wang N; Zhang Q; Ning B; Luo L; Fang Y
Biomed Pharmacother; 2017 Jun; 90():368-374. PubMed ID: 28380412
[TBL] [Abstract][Full Text] [Related]
17. Effect of adenosine A(2A) receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated rats.
Gołembiowska K; Dziubina A
Neurotox Res; 2012 Feb; 21(2):222-30. PubMed ID: 21830163
[TBL] [Abstract][Full Text] [Related]
18. L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.
Pinna A; Bonaventura J; Farré D; Sánchez M; Simola N; Mallol J; Lluís C; Costa G; Baqi Y; Müller CE; Cortés A; McCormick P; Canela EI; Martínez-Pinilla E; Lanciego JL; Casadó V; Armentero MT; Franco R
Exp Neurol; 2014 Mar; 253():180-91. PubMed ID: 24412491
[TBL] [Abstract][Full Text] [Related]
19. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.
Parada A; Loureiro AI; Vieira-Coelho MA; Hainzl D; Soares-da-Silva P
Eur J Pharmacol; 2001 May; 420(1):27-32. PubMed ID: 11412836
[TBL] [Abstract][Full Text] [Related]
20. Catechol-O-methyltransferase inhibition increases striatal L-dopa and dopamine: an in vivo study in rats.
Brannan T; Martínez-Tica J; Yahr MD
Neurology; 1992 Mar; 42(3 Pt 1):683-5. PubMed ID: 1549240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
